https://www.thebodypro.com/category/hiv-epidemiology/tag/conference-coverage
HIV Epidemiology

Conference Coverage

The Latest

No Increased Resistance With Once-Daily Dosing of Abacavir and 3TC Than Twice-Daily Dosing in the ARROW Trial Img

No Increased Resistance With Once-Daily Dosing of Abacavir and 3TC Than Twice-Daily Dosing in the ARROW Trial

Once-daily dosing of abacavir (ABC) and lamivudine (3TC) was non-inferior to twice-daily dosing in development of viral resistance in the ARROW trial, according to data presented at the 8th International Workshop on HIV Pediatrics.

Pediatric HIV Cure Studied in Infant Monkeys Img

Pediatric HIV Cure Studied in Infant Monkeys

On behalf of IFARA, Fred Schaich spoke with Ann Chahroudi about the pediatric HIV cure research in infant rhesus macaques that was presented at this year's International AIDS Conference and why no single cure strategy will likely be effective.

HIV Therapy for Breastfeeding Mothers Can Virtually Eliminate Transmission to Babies Img

HIV Therapy for Breastfeeding Mothers Can Virtually Eliminate Transmission to Babies

For HIV-infected mothers whose immune system is in good health, taking a three-drug antiretroviral regimen during breastfeeding essentially eliminates HIV transmission by breast milk to their infants, according to results from a large clinical trial ...

No Effect of Tenofovir on Infant Bone Mineral Content in African Study Img

No Effect of Tenofovir on Infant Bone Mineral Content in African Study

A report from the PROMISE study showed no adverse bone mineral effect, linked to maternal tenofovir disoproxil fumarate (TDF), in exposed infants.

Use of Modelling to Predict Pediatric Dosing of Long-Acting Antiretrovirals Img

Use of Modelling to Predict Pediatric Dosing of Long-Acting Antiretrovirals

Physiologically based pharmacokinetic modeling can help predict dosing strategies for long-acting antiretrovirals, according to data presented at CROI 2016.

Nevirapine Dosing for Treatment of Neonates Img

Nevirapine Dosing for Treatment of Neonates

Population modelling and pharmacokinetic simulations shown at CROI 2016 predicted dosing regimens to achieve target nevirapine treatment concentrations in term and late preterm infants.

Riding the Waves in Uncharted Waters: Excitement and Hope for Transmasculine People in HIV Research Img

Riding the Waves in Uncharted Waters: Excitement and Hope for Transmasculine People in HIV Research

"I cried listening to Dr. Tonia Poteat's CROI 2016 plenary presentation in February, HIV in Transgender Populations: Charted and Uncharted Waters," writes Brandyn Gallagher. "A few times, actually."

Trans People Remain Largely Invisible in Health Data Img

Trans People Remain Largely Invisible in Health Data

Tonia Poteat, Ph.D., who delivered the first-ever plenary session focused on transgender people at CROI 2016, says it is unclear why the federal government cannot mandate inclusion of gender identity questions in the Behavioral Risk Factor Surveillan...

Transgender People at High Risk for HIV, But Little Is Known About Prevention and Treatment Img

Transgender People at High Risk for HIV, But Little Is Known About Prevention and Treatment

"There is probably no population that is both more heavily impacted [by HIV] and less discussed around the world than transgender people," said Susan Buchbinder, M.D., during a CROI 2016 presentation.

Dolutegravir: 48-Week Results in Children Age 6 to 12 Years Old Img

Dolutegravir: 48-Week Results in Children Age 6 to 12 Years Old

Dolutegravir is safe and effective in children age 6-12 years, according to results presented at CROI 2016.